Location Directory

Clinical trials in New Haven, Connecticut

This page shows live ClinicalTrials.gov search results for New Haven, Connecticut, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

2494

Shown on this page

Local exact-city summaries

2494

Based on exact city/state matches in the local index.

Local exact-city recruiting

609

Live official results below use the broader ClinicalTrials.gov location search.

The trial list below is retrieved from the live ClinicalTrials.gov search API for New Haven, Connecticut. Results on this page are currently sorted by Recently updated. Use the filter controls below to narrow by condition, treatment, sponsor, recruitment status, phase, study type, sex, or age.

Showing 1–12 of 2,494 matching trials in New Haven, CT.

Indexed local directory records.

The summary panels and records below use exact city/state matches from the local directory for New Haven, CT. Use the filters or full search link when you want broader live ClinicalTrials.gov location matching.

Top conditions in local exact-city summaries

Breast Cancer 70 Colorectal Cancer 40 Ovarian Cancer 39 Prostate Cancer 35 Acute Myeloid Leukemia 34 Alzheimer's Disease 34

Top sponsors in local exact-city summaries

Yale University 368 National Cancer Institute (NCI) 210 Children's Oncology Group 102 Pfizer 80 AstraZeneca 51 Hoffmann-La Roche 48

Top therapies in local exact-city summaries

Pembrolizumab 99 Carboplatin 93 Paclitaxel 77 Cisplatin 71 Cyclophosphamide 67 Nivolumab 56

Indexed official records

Open in full search

Conditions: T Cell Malignancies
Interventions: ELA026; Drug
Lead sponsor: Electra Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 4
States / cities: New Haven, Connecticut • Atlanta, Georgia • Grand Rapids, Michigan + 1 more

Conditions: Brain Cancer, Central Nervous System Diseases, GBM, Glioblastoma (GBM), Glioblastoma Multiforme (GBM), Glioma, Newly Diagnosed Glioblastoma
Interventions: silevertinib in combination with temozolomide, temozolomide (TMZ); Drug
Lead sponsor: Black Diamond Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Springdale, Arkansas • Los Angeles, California • New Haven, Connecticut + 4 more

Conditions: Epilepsy, Epilepsy (Treatment Refractory)
Interventions: Receipt of the Minder System (implantable sub-scalp continuous electroencephalographic (EEG) monitoring (iCEM) system); Device
Lead sponsor: Epiminder America, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 17
States / cities: Phoenix, Arizona • Irvine, California • Palo Alto, California + 13 more

Conditions: Relapsed/Refractory Primary Central Nervous System Lymphoma
Interventions: Rituximab, Temozolomide, Tirabrutinib; Drug
Lead sponsor: Ono Pharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 10
States / cities: Scottsdale, Arizona • Fullerton, California • New Haven, Connecticut + 5 more

Conditions: Untreated Follicular Lymphoma
Interventions: Surovatamig, R-CHOP, R-CVP, BR
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,018 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 51
States / cities: Huntsville, Alabama • Anchorage, Alaska • Phoenix, Arizona + 45 more

Conditions: Acute Myeloid Leukemia
Interventions: Azacitidine, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Gilteritinib, Venetoclax; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 219
States / cities: Tucson, Arizona • Little Rock, Arkansas • Berkeley, California + 175 more

Conditions: Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma
Interventions: Biospecimen Collection, Cyclophosphamide, Doxorubicin, Durvalumab, Genetic Testing, Mammography, Paclitaxel, Quality-of-Life Assessment; Procedure · Drug · Biological + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 3,680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 534
States / cities: Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 411 more

Conditions: Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions: Biospecimen Collection, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab, cfDNA or ctDNA Measurement; Procedure · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 992 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 487
States / cities: Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 367 more

Conditions: Adult T-cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Breast Implant-Associated Anaplastic Large Cell Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Chronic Lymphoproliferative Disorder of NK Cells, Enteropathy-associated T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Follicular T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Mycosis Fungoides, NK-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Sezary Syndrome, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), T-cell Large Granular Lymphocytic Leukemia, T-cell Lymphoma, T-cell Prolymphocytic Leukemia
Interventions: Optional Blood Sample and Nail Sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 26
States / cities: Duarte, California • San Diego, California • San Francisco, California + 20 more

Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Echocardiography Test, FDG-Positron Emission Tomography and Computed Tomography Scan, Lumbar Puncture, Multigated Acquisition Scan, Tovorafenib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 180 Days to 22 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 104
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 82 more

Conditions: Acute Ischemic Stroke, Blood Pressure Variability
Interventions: Not listed
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: New Haven, Connecticut • Chicago, Illinois • Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
Interventions: Allogeneic Hematopoietic Stem Cell Transplantation, Azacitidine, Best Practice, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Busulfan, Chest Radiography, Computed Tomography, Cytarabine, Daunorubicin Hydrochloride, Decitabine and Cedazuridine, Echocardiography Test, Emavusertib, Enasidenib, Epoetin Alfa, Fludarabine, Gemtuzumab Ozogamicin, Gilteritinib, Liposome-encapsulated Daunorubicin-Cytarabine, Luspatercept, Melphalan, Multigated Acquisition Scan, Mutation Carrier Screening, Olutasidenib, Placebo Administration, Positron Emission Tomography, Total-Body Irradiation, Venetoclax; Procedure · Drug · Other + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 335
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 258 more

Clinical trials in New Haven, Connecticut

Filter and sort this location

Top conditions in local exact-city summaries

Top sponsors in local exact-city summaries

Top therapies in local exact-city summaries

Indexed official records

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Diagnosing Epilepsy To EffeCT Change

IGNITE: Study of Tirabrutinib vs Rituximab/Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

A Registry for People With T-cell Lymphoma

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

Blood Pressure Variability and Ischemic Stroke Outcome

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)